Disease-associated single amino acid mutation in the calf-1 domain of integrin α3 leads to defects in its processing and cell surface expression

Biochemical and Biophysical Research Communications

Volumn 441, Issue 4, 2013, Pages 988-993

  Yamada, Masashi ^a   Sekiguchi, Kiyotoshi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Basement membrane; CD151; Glycosylation; Laminin; Posttranslational modification; Tetraspanin

Indexed keywords

ALPHA3 INTEGRIN; ARGININE; BETA1 INTEGRIN; CD151 ANTIGEN; GLUTAMIC ACID; GLUTAMINE; MUTANT PROTEIN; PROLINE; TETRASPANIN;

AMINO ACID SUBSTITUTION; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENDOPLASMIC RETICULUM; EPIDERMOLYSIS BULLOSA; EPITHELIUM CELL; GOLGI COMPLEX; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INTERSTITIAL LUNG DISEASE; MISSENSE MUTATION; NEPHRITIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STRUCTURE; WILD TYPE;

BASEMENT MEMBRANE; CD151; DMEM; DULBECCO'S MODIFIED EAGLE'S MEDIUM; ENDOPLASMIC RETICULUM; ER; GLYCOSYLATION; LAMININ; MAB; MONOCLONAL ANTIBODY; PAB; PBS; PHOSPHATE-BUFFERED SALINE; POLYCLONAL ANTIBODY; POSTTRANSLATIONAL MODIFICATION; TETRASPANIN;

AMINO ACID SUBSTITUTION; ANTIGENS, CD151; ARGININE; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM; GOLGI APPARATUS; HUMANS; INTEGRIN ALPHA3; KIDNEY DISEASES; LUNG DISEASES; MUTATION, MISSENSE; PROLINE; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; SKIN DISEASES;

EID: 84888823769     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.11.003     Document Type: Article

References (19)

1. Nishiuchi R., Takagi J., Hayashi M., Ido H., Yagi Y., Sanzen N., Tsuji T., Yamada M., Sekiguchi K. Ligand-binding specificities of laminin-binding integrins: a comprehensive survey of laminin-integrin interactions using recombinant α3β1, α6β1, α7β1 and α6β4 integrins. Matrix Biol. 2006, 25:189-197.
2. Campbell I.D., Humphries M.J. Integrin structure, activation, and interactions. Cold Spring Harb. Perspect. Biol. 2011, 3.
3. Lissitzky J.C., Luis J., Munzer J.S., Benjannet S., Parat F., Chretien M., Marvaldi J., Seidah N.G. Endoproteolytic processing of integrin pro-α subunits involves the redundant function of furin and proprotein convertase (PC) 5A, but not paired basic amino acid converting enzyme (PACE) 4, PC5B or PC7. Biochem. J. 2000, 346:133-138.
4. Kreidberg J.A., Donovan M.J., Goldstein S.L., Rennke H., Shepherd K., Jones R.C., Jaenisch R. A3β1 integrin has a crucial role in kidney and lung organogenesis. Development 1996, 122:3537-3547.
5. DiPersio C.M., Hodivala-Dilke K.M., Jaenisch R., Kreidberg J.A., Hynes R.O. A3β1 Integrin is required for normal development of the epidermal basement membrane. J. Cell Biol. 1997, 137:729-742.
6. Has C., Sparta G., Kiritsi D., Weibel L., Moeller A., Vega-Warner V., Waters A., He Y., Anikster Y., Esser P., Straub B.K., Hausser I., Bockenhauer D., Dekel B., Hildebrandt F., Bruckner-Tuderman L., Laube G.F. Integrin α3 mutations with kidney, lung, and skin disease. N. Engl. J. Med. 2012, 366:1508-1514.
7. Nicolaou N., Margadant C., Kevelam S.H., Lilien M.R., Oosterveld M.J., Kreft M., van Eerde A.M., Pfundt R., Terhal P.A., van der Zwaag B., Nikkels P.G., Sachs N., Goldschmeding R., Knoers N.V., Renkema K.Y., Sonnenberg A. Gain of glycosylation in integrin α3 causes lung disease and nephrotic syndrome. J. Clin. Invest. 2012, 122:4375-4387.
8. Yamada M., Mugnai G., Serada S., Yagi Y., Naka T., Sekiguchi K. Substrate-attached materials are enriched with tetraspanins and are analogous to the structures associated with rear-end retraction in migrating cells. Cell Adhes. Migr. 2013, 7:304-314.
9. Nishiuchi R., Sanzen N., Nada S., Sumida Y., Wada Y., Okada M., Takagi J., Hasegawa H., Sekiguchi K. Potentiation of the ligand-binding activity of integrin α3β1 via association with tetraspanin CD151. Proc. Natl. Acad. Sci. USA 2005, 102:1939-1944.
10. Yamada M., Tamura Y., Sanzen N., Sato-Nishiuchi R., Hasegawa H., Ashman L.K., Rubinstein E., Yanez-Mo M., Sanchez-Madrid F., Sekiguchi K. Probing the interaction of tetraspanin CD151 with integrin α3β1 using a panel of monoclonal antibodies with distinct reactivities toward the CD151-integrin α3β1 complex. Biochem. J. 2008, 415:417-427.
11. Yamada M., Sumida Y., Fujibayashi A., Fukaguchi K., Sanzen N., Nishiuchi R., Sekiguchi K. The tetraspanin CD151 regulates cell morphology and intracellular signaling on laminin-511. FEBS J. 2008, 275:3335-3351.
12. Berditchevski F., Gilbert E., Griffiths M.R., Fitter S., Ashman L., Jenner S.J. Analysis of the CD151-α3β1 integrin and CD151-tetraspanin interactions by mutagenesis. J. Biol. Chem. 2001, 276:41165-41174.
13. Hemler M.E. Tetraspanin functions and associated microdomains. Nat. Rev. Mol. Cell Biol. 2005, 6:801-811.
14. Stipp C.S. Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets. Expert Rev. Mol. Med. 2010, 12:e3.
15. Yauch R.L., Kazarov A.R., Desai B., Lee R.T., Hemler M.E. Direct extracellular contact between integrin α3β1 and TM4SF protein CD151. J. Biol. Chem. 2000, 275:9230-9238.
16. Gonzalez-Manchon C., Fernandez-Pinel M., Arias-Salgado E.G., Ferrer M., Alvarez M.V., Garcia-Munoz S., Ayuso M.S., Parrilla R. Molecular genetic analysis of a compound heterozygote for the glycoprotein (GP) IIb gene associated with Glanzmann's thrombasthenia: disruption of the 674-687 disulfide bridge in GPIIb prevents surface exposure of GPIIb-IIIa complexes. Blood 1999, 93:866-875.
17. Rosenberg N., Yatuv R., Sobolev V., Peretz H., Zivelin A., Seligsohn U. Major mutations in calf-1 and calf-2 domains of glycoprotein IIb in patients with Glanzmann thrombasthenia enable GPIIb/IIIa complex formation, but impair its transport from the endoplasmic reticulum to the Golgi apparatus. Blood 2003, 101:4808-4815.
18. MacArthur M.W., Thornton J.M. Influence of proline residues on protein conformation. J. Mol. Biol. 1991, 218:397-412.
19. Smith M.H., Ploegh H.L., Weissman J.S. Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. Science 2011, 334:1086-1090.